Recent developments in prostate cancer biomarker research: therapeutic implications

Authors

  • Sujitra Detchokul,

    1. Clinical Pharmacology and Therapeutics Unit, Department of Medicine (Austin Health/Northern Health), the University of Melbourne, Heidelberg, Victoria 3084, Australia
    Search for more papers by this author
  • Albert G. Frauman

    1. Clinical Pharmacology and Therapeutics Unit, Department of Medicine (Austin Health/Northern Health), the University of Melbourne, Heidelberg, Victoria 3084, Australia
    Search for more papers by this author

Professor Albert G. Frauman MD, FRACP, FACP, FACCP, Department of Medicine, Austin Campus, the University of Melbourne, Clinical Pharmacology and Therapeutics Unit, Heidelberg, Victoria 3084, Australia.
Tel.: + 613 9496 5486
Fax: + 613 9496 3510
E-mail: albertf@unimelb.edu.au

Abstract

This review aims to present an overview of recent clinical trials targeting biomarkers in advanced prostate cancer. We searched ClinicalTrials.gov for early phase clinical trials on treatments of prostate cancer that have been recently completed, are ongoing or are actively recruiting participants. Drug targets and their mechanism of actions were assessed and summarized. Trials were categorized according to prostate cancer biomarkers that have potential as therapeutic targets. A total of 19 new therapeutic agents for the treatment of prostate cancer are included in this review. Trials are summarized according to the targeted biomarkers and are categorized into five therapeutic approaches: prostate cancer vaccine, epigenetic therapy, pro-apoptotic agents, prostate cancer antibodies and anti-angiogenesis approach. Some of the therapeutic agents reviewed showed promising results, warranting further investigation in late phase clinical trials. Recent novel prostate cancer biomarkers that made it through clinical trials and their relevance as drug targets are summarized. This review emphasizes the importance of specific prostate cancer biomarkers and their potentials as targets of the disease. Some clinical trials of targeted treatments in prostate cancer show promising results. Better understanding of disease mechanisms should potentially lead to more specific treatments for individual patients.

Ancillary